CalciMedica (NASDAQ:CALC) Issues Earnings Results

CalciMedica (NASDAQ:CALC) issued its quarterly earnings data on Tuesday. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.17), Zacks reports.

CalciMedica Price Performance

CALC traded up $0.00 during mid-day trading on Wednesday, hitting $0.66. The stock had a trading volume of 30,990 shares, compared to its average volume of 1,068,705. The stock’s fifty day simple moving average is $0.82 and its 200-day simple moving average is $0.84. The firm has a market capitalization of $10.41 million, a price-to-earnings ratio of -0.50 and a beta of 0.91. CalciMedica has a 1-year low of $0.46 and a 1-year high of $7.20.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on CALC. Weiss Ratings upgraded shares of CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 29th. HC Wainwright restated a “neutral” rating on shares of CalciMedica in a research report on Wednesday, July 29th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $10.00.

Insider Activity

In other news, Director Fred A. Middleton acquired 248,972 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was acquired at an average price of $0.80 per share, for a total transaction of $199,177.60. Following the transaction, the director directly owned 1,063,272 shares in the company, valued at approximately $850,617.60. This represents a 30.57% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. 28.25% of the stock is owned by company insiders.

Institutional Investors Weigh In On CalciMedica

Several large investors have recently modified their holdings of CALC. Boothbay Fund Management LLC bought a new position in shares of CalciMedica during the 4th quarter valued at about $506,000. Renaissance Technologies LLC raised its holdings in CalciMedica by 26.1% during the 4th quarter. Renaissance Technologies LLC now owns 88,300 shares of the company’s stock worth $582,000 after buying an additional 18,300 shares during the period. Envestnet Asset Management Inc. lifted its stake in CalciMedica by 58.2% in the second quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock valued at $149,000 after buying an additional 34,386 shares in the last quarter. Jane Street Group LLC bought a new position in CalciMedica in the fourth quarter valued at approximately $127,000. Finally, Cetera Investment Advisers boosted its holdings in shares of CalciMedica by 33.1% in the second quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock valued at $58,000 after buying an additional 9,045 shares during the period.

CalciMedica Company Profile

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.